Glenmark Pharma.

Glenmark launched RYALTRIS Nasal Spray in Brazil for moderate to severe allergic-rhinitis symptoms in adults and adolescents aged 12 and above. The launch followed approval from Brazil’s health regulator, ANVISA, earlier in the year, and introduced the country’s first olopatadine-containing intranasal combination therapy. RYALTRIS, which combines olopatadine hydrochloride and mometasone furoate, had been approved in 57 markets worldwide. Glenmark’s FY26 consolidated revenue was about ₹17,000 crore, with branded markets accounting for more than 60% of revenue in FY25.

Powered by Tijori

Sept 11 (Reuters) - Glenmark Pharmaceuticals Limited GLEN.NS:

• GLENMARK PHARMA - UNIT LAUNCHES RYALTRIS NASAL SPRAY IN BRAZIL FOR ALLERGIC RHINITIS

Source text: ID:nBSE6bmXc7

Further company coverage: GLEN.NS

(([email protected];))

Aug 21 (Reuters) - Glenmark Pharmaceuticals Limited GLEN.NS:

• GLENMARK PHARMA - US UNIT LAUNCHES CALCIUM GLUCONATE INJECTION USP IN MULTIPLE VIAL SIZES

Source text: ID:nBSE6tc3QQ

Further company coverage: GLEN.NS

(([email protected];))

Glenmark Pharmaceuticals received U.S. FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg per spray, a generic equivalent to Haleon's Flonase nasal spray. Glenmark Pharmaceuticals Inc., USA, will distribute the product in the United States. The market for Flonase and available therapeutic equivalents recorded annual sales of about $295.2 million in the 12 months ended June 2026, according to IQVIA. North America accounted for about 42% of Glenmark's FY26 consolidated revenue, while core North American revenue grew 19.8% in the first quarter of FY27.

Powered by Tijori

** Pharmaceutical company Glenmark Pharma's shares GLEN.NS rise as much as 3.54%, the biggest single-session jump in three weeks, to 2326 rupees apiece

** Rise after GLEN announces the receipt of U.S. drug regulator's approval for nasal spray, Fluticasone Propionate, therapeutically equivalent to the drug Flonase nasal spray, used to treat hay fever, nasal congestion

** According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal spray market achieved annual sales of $295.2 million

** GLEN shares are up 13.5% in 2026 so far, almost mirroring the 16.2% rise in pharma index .NIPHARM, according to exchange data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]))

** Shares of India's Glenmark Pharmaceuticals GLEN.NS fall as much as 3.22% to 2,162 rupees

** On Friday, GLEN posted 53.6% y-o-y jump in adjusted Q1 profit, led by strong demand for its drugs that treat long-term illnesses, while revenue rose 23.1% y/y

** Company's Q1 revenue, EBITDA and adjusted profit missed estimates despite healthy year-on-year growth, Motilal Oswal says

** Brokerage says the company's Q1 sales of 40.2 billion rupees were below its estimate of 40.9 billion rupees

** GLEN rated "buy" on average by 9 analysts, median PT 2,575 rupees - data compiled by LSEG

** YTD stock up 9.44%

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

July 31 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS posted a 53.6% jump in adjusted first-quarter profit on Friday, led by strong demand for its drugs that treat long-term illnesses.

The company's consolidated profit before exceptional items and taxes rose to 6.43 billion rupees ($67.41 million) for the quarter ended June 30, from 4.19 billion rupees a year ago.

Here are some key details:

• Strong demand for Glenmark's respiratory, dermatology and oncology products helped cushion against weak pricing and fierce competition in its key North American and European markets.

• Sales from its India formulations business rose 15.5% year-on-year, while net sales from its core operations in North America and Europe increased 41.1% and 11.9%, respectively

• Overall revenue was up 23.1% at 40.18 billion rupees, while expenses rose 19.8%.

($1 = 95.3800 Indian rupees)

(Reporting by Mridula Kumar in Bengaluru; Editing by Diti Pujara)

(([email protected]))

July 21 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - RECEIVES FDA APPROVAL TO EXPAND RYALTRIS USE FOR CHILDREN AGED 6 TO UNDER 12

• GLENMARK PHARMA - RYALTRIS NOW APPROVED IN U.S. FOR ADULTS AND CHILDREN AGED 6 YEARS AND OLDER

Source text: ID:nNSE8LMtD9

Further company coverage: GLEN.NS

(([email protected];))

** Shares of Glenmark Pharmaceuticals GLEN.NS fall as much as 2.5% to 2,229 rupees; set for the third session of losses

** A coalition of 48 states and territories in the United States reached a $29.6 million settlement with GLEN and will make installment payments through 2030

** They accuse the co of helping inflate prices of generic drugs and limiting competition

** GLEN denied wrongdoing but agreed to cooperate with ongoing state lawsuits and make changes to ensure compliance with antitrust law

** Ten analysts have a "Buy" rating on average; median PT is 2,575 rupees - data compiled by LSEG

** YTD, GLEN up 10.5%

(Reporting by Urvi Dugar in Bengaluru)

(([email protected];))

Updates July 7 story to add July 8 Adani comment in paragraphs 8-9, 15, bullet

By Aditya Kalra

NEW DELHI, July 7 (Reuters) - An Indian investigation found that Mumbai international airport's duty-free shops run by billionaire Gautam Adani's business group breached the law by selling nicotine pouches, which the government considers a public health hazard, according to documents from the investigation.

Adani denies wrongdoing and is asking judges to declare that a law covering drugs and cosmetics does not apply to duty-free shops and nicotine pouches, according to court papers reviewed by Reuters. Lawyers say the case could set a precedent on how India regulates sales at such outlets and a government win could block sales of one of the world's fastest-growing nicotine products in India's airports.

India banned e-cigarettes and approved certain nicotine replacements like patches and chewing gums following a registration process under the Drugs and Cosmetics Act. Nicotine pouches remain illegal and unapproved.

INDIA DEFINES NICOTINE POUCHES AS 'A DRUG'

The Indian government says tobacco kills 1.35 million people each year in India. A government study in June called nicotine pouches "a new and largely unregulated public health concern", with widespread illegal sales and consumption among people aged 18 to 40.

After receiving complaints from anti-nicotine group Mothers Against Vaping, India's drug department inspected duty-free shops at Mumbai's international airport in March and found imported nicotine pouches were being sold in the departure zone without the necessary approvals, government documents show.

"Nicotine pouches also fall under the definition of a drug ... a valid registration certificate and import license are mandatory," an assistant drugs controller wrote in an April 2 letter to the airport's customs authority, attaching an "investigation report".

The government asked Mumbai Travel Retail, a joint venture led by Adani with Dubai's Flemingo, to discontinue sales of nicotine pouches and seek approvals, government letters show.

Adani did not respond to Reuters queries ahead of the story’s publication. Late on Wednesday, its spokesperson said in an email that the characterisation of "the matter as a 'breach of law' is premature and legally unsustainable", adding that Mumbai Travel Retail has “challenged the regulatory interpretation through judicial review.”

“International passengers arriving in India may lawfully carry nicotine pouches purchased overseas for personal consumption," the Adani statement said. "Yet the sale of identical products through an international duty-free channel has been treated differently. This apparent inconsistency forms part of the legal challenge."

Flemingo and the Indian health and customs authority did not respond to requests for comment.

Selling a drug without a license could draw a prison term of at least three years and a fine of at least 100,000 rupees ($1,000) or three times the value of the drugs confiscated, whichever is higher.

Reuters is first to report the details of the investigation into Adani sales and its court challenge in Mumbai.

Adani's firm has told authorities the shops in the international departure area conduct business "beyond the customs frontiers of India" and are outside the reach of domestic regulations, its non-public High Court filing shows.

CAN GUNS BE SOLD AT AIRPORT?

Asked about the Adani group's point, Murali Neelakantan, former general counsel at Indian drugmakers Cipla and Glenmark Pharmaceuticals, told Reuters: "If a murder occurs in the store, will Indian police have no powers to arrest? They will have ... Can (the store) sell guns or ammunition? No."

The Adani statement responded: "Firearms are prohibited from duty free retail world over because they pose an inherent threat to aviation safety. Drawing a parallel between firearms and regulated nicotine products has no bearing on the legal issues before the Court."

On June 24, judges in Mumbai's High Court said "no coercive action" should be taken on the existing stock of pouches at Mumbai's duty-free shops, scheduling the case for a July 14 hearing.

Adani runs eight airports in India and is targeting an $11 billion expansion that includes a bet on duty-free offerings. At Mumbai's international airport, it runs more than 30 duty-free shops.

In court, Adani said nicotine pouches "are not a drug" and are a "recent innovation" that was not anticipated by existing tobacco control laws, documents show.

Since August, Adani's firm imported Philip Morris' PM.N Zyn nicotine pouches in various flavours worth more than $29,000, and the White Fox brand from Swedish Smokeless Solutions worth $7,700, customs records showed. Those companies did not respond to Reuters queries.

Philip Morris says Zyn's U.S. sales doubled last year from 2023. The June Indian government study said both Zyn and White Fox were being sold by Indian vendors illegally.

Separately, Flemingo Dutyfree has told the High Court it operates shops at international seaports — including in Mumbai — and fears similar actions as it was "in the process of stocking" nicotine pouches, documents show.

Seeking licenses for nicotine pouches will compel suppliers to withdraw them from the market, making "the duty free industry in India unattractive to passengers," it said.

(Reporting by Aditya Kalra; Additional reporting by Arpan Chaturvedi; Editing by Thomas Derpinghaus and William Mallard)

((Email: [email protected]; X: @adityakalra;))

By Aditya Kalra

NEW DELHI, July 7 (Reuters) - An Indian investigation found that Mumbai international airport's duty-free shops run by billionaire Gautam Adani's business group breached the law by selling nicotine pouches, which the government considers a public health hazard, according to documents from an investigation.

Adani denies wrongdoing and is asking judges to declare that a law covering drugs and cosmetics does not apply to duty-free shops and nicotine pouches, according to court papers reviewed by Reuters. Lawyers say the case could set a precedent on how India regulates sales at such outlets and a government win could block sales of one of the world's fastest-growing nicotine products in India's airports.

India banned e-cigarettes and approved certain nicotine replacements like patches and chewing gums following a registration process under the Drugs and Cosmetics Act. Nicotine pouches remain illegal and unapproved.

Tobacco kills 1.35 million people each year in India and a government study in June called nicotine pouches "a new and largely unregulated public health concern," with widespread illegal sales and consumption among people aged 18 to 40.

After receiving complaints from anti-nicotine group Mothers Against Vaping, India's drug department inspected duty-free shops at Mumbai's international airport in March and found imported nicotine pouches were being sold in the departure zone without the necessary approvals, government documents show.

"Nicotine pouches also fall under the definition of a drug ... a valid registration certificate and import license are mandatory," an assistant drugs controller wrote in an April 2 letter to the airport's customs authority, attaching an "investigation report."

Mumbai Travel Retail, a joint venture led by Adani with Dubai's Flemingo, was asked to discontinue sales of nicotine pouches and seek approvals, government letters show.

Adani declined to comment. Flemingo and the Indian health and customs authority did not respond to requests for comment.

Selling a drug without a license could draw a prison term of at least three years and a fine of at least 100,000 rupees ($1,049), or three times the value of the drugs confiscated, whichever is higher.

Reuters is first to report the details of the investigation into Adani sales and its court challenge in Mumbai.

CAN GUNS BE SOLD AT AIRPORT?

Adani's firm has told authorities the shops in the international departure area conduct business "beyond the customs frontiers of India" and are outside the regulatory reach of domestic regulations, its non-public High Court filing shows.

"If a murder occurs in the store, will Indian police have no powers to arrest? They will have ... Can they sell guns or ammunition? No," said Murali Neelakantan, who was previously general counsel at Indian drugmakers Cipla and Glenmark Pharmaceuticals.

On June 24, judges in Mumbai's High Court said "no coercive action" should be taken on the existing stock of pouches at Mumbai's duty-free shops, scheduling the case for a July 14 hearing.

POUCHES A "RECENT INNOVATION"

Adani runs eight airports in India and is targeting an $11 billion expansion that includes a bet on duty-free offerings. At Mumbai's international airport, it runs more than 30 duty-free shops.

In court, Adani said nicotine pouches "are not a drug" and are a "recent innovation" that was not anticipated by existing tobacco control laws, documents show.

Since August, Adani's firm imported Philip Morris' PM.N Zyn nicotine pouches in various flavours worth more than $29,000, and the White Fox brand from Swedish Smokeless Solutions worth $7,700, customs records showed. The companies did not respond to Reuters queries.

Philip Morris says Zyn's U.S. sales in 2025 doubled from 2023. The June Indian government study said both Zyn and White Fox were being sold by Indian vendors illegally.

Separately, Flemingo Dutyfree has told the High Court it operates shops at international seaports - including in Mumbai - and fears similar actions as it was "in the process of stocking" nicotine pouches, documents show.

Seeking licenses for nicotine pouches will compel suppliers to withdraw them from the market, making "the duty free industry in India unattractive to passengers," it said.

(Reporting by Aditya Kalra; Additional reporting by Arpan Chaturvedi; Editing by Thomas Derpinghaus)

((Email: [email protected]; X: @adityakalra;))

July 6 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - UNIT LAUNCHES OLANZAPINE FOR INJECTION, 10 MG/VIAL, SINGLE-DOSE VIAL

Source text: ID:nNSEby57T0

Further company coverage: GLEN.NS

(([email protected];))

July 2 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - UNIT ADVANCES MULTI-COUNTRY PHASE 3 TRIAL FOR TRASTUZUMAB REZETECAN IN PLATINUM-RESISTANT OVARIAN CANCER

Source text: ID:nBSE55fTLy

Further company coverage: GLEN.NS

(([email protected];))

June 11 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - LAUNCHES WINLEVI (CLASCOTERONE) 10 MG/G CREAM IN KEY EUROPEAN MARKETS

Source text: ID:nBSE1cHzrV

Further company coverage: GLEN.NS

(([email protected];;))

June 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - GLENMARK PHARMACEUTICALS INC USA LAUNCHES LACOSAMIDE INJECTION USP

Source text: ID:nBSE7xtZqY

Further company coverage: GLEN.NS

(([email protected];))

May 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA Q4 CONSOL NET PROFIT 3.01 BILLION RUPEES

• GLENMARK PHARMA Q4 CONSOL NET SALES 37.6 BILLION RUPEES

• GLENMARK PHARMA - DECLARES DIVIDEND OF 2.5 RUPEES PER SHARE

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];))

May 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA - LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 MG/VIAL AND 1 G/VIAL

Source text: ID:nBSE93bDRP

Further company coverage: GLEN.NS

(([email protected];))

April 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• RECEIVES U.S. FDA APPROVAL FOR PROGESTERONE VAGINAL INSERTS, 100 MG

Source text: ID:nNSE8j4qcP

Further company coverage: GLEN.NS

(([email protected];))

April 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GETS TAX DEMAND AND PENALTY OF 160.5 MILLION RUPEES EACH

Source text: ID:nnAZN4SOJUW

Further company coverage: GLEN.NS

(([email protected];))

SHANGHAI, March 25 (Reuters) - Jiangsu Hengrui Pharmaceuticals 600276.SS, China's biggest drugmaker by market value, reported fourth-quarter profit below market expectations on Wednesday, as income from business development deals has failed to appear.

The specialist in oncology, neurology, immunology, respiratory, metabolic and cardiovascular drugs has expanded licensing deals and developed more innovative drugs amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.

In September, Hengrui agreed to grant a paid licence for its innovative cancer drug, trastuzumab rezetecan, to the Swiss arm of India's Glenmark Pharmaceuticals GLEN.NS, with an upfront payment of $18 million under the deal.

The deal was a part of a string of new licensing agreements earlier last year with overseas drugmakers such as Merck MRK.N and Britain's GSK GSK.L.

Hengrui's revenue from innovative drug sales increased 26.09% in 2025 but revenue from generic drug slipped, it said in its annual report.

The company recorded 1.96 billion yuan ($284.10 million) in net profit attributable to shareholders for the quarter ended December 31, its annual report showed, below HSBC Qianhai Securities analysts' estimate of 2.7 billion yuan.

Net profit for the entire 2025 rose 21.69% to 7.71 billion yuan.

($1 = 6.8989 Chinese yuan renminbi)

(Reporting by Andrew Silver, Editing by Louise Heavens)

March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.

The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.

Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.

Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.

Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:

SUN PHARMACEUTICAL SUN.NS

India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.

DR REDDY'S LABORATORIES REDY.NS

The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.

ZYDUS LIFESCIENCES ZYDU.NS

The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.

TORRENT PHARMACEUTICALS TORP.NS

The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.

GLENMARK PHARMACEUTICALS GLEN.NS

Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).

ALKEM LABORATORIES ALKE.NS

The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.

ERIS LIFESCIENCES ERIS.NS

The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.

($1 = 93.9000 Indian rupees)

(Reporting by Rishika Sadam; Editing by Rashmi Aich)

(([email protected];))

March 4 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK SPECIALTY SA RECEIVES U.S. FDA APPROVAL FOR FLUTICASONE PROPIONATE INHALATION AEROSOL USP, 44 MCG PER ACTUATION, WITH 180-DAY COMPETITIVE GENERIC THERAPY EXCLUSIVITY

• GLENMARK PHARMA - TO DISTRIBUTE FLUTICASONE PROPIONATE INHALATION AEROSOL IN U.S. STARTING MARCH 2026

Source text: ID:nPn2YYB0ka

Further company coverage: GLEN.NS

(([email protected];))

Feb 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• TO LAUNCH SODIUM PHOSPHATES INJECTION IN USA

• SODIUM PHOSPHATES INJECTION DISTRIBUTION TO BEGIN IN APRIL 2026

Source text: ID:nNSE1w4VMD

Further company coverage: GLEN.NS

(([email protected];;))

Jan 30 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:

• GLENMARK PHARMA Q3 CONSOL NET PROFIT 4.03 BILLION RUPEES

• GLENMARK PHARMA Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 39.01 BILLION RUPEES

Source text: [ID:]

Further company coverage: GLEN.NS

(([email protected];))

** Shares of Glenmark Pharma GLEN.NS rise 2.8% to 2,047.3 rupees, their highest in over 3 weeks

** Drugmaker starts phase 3 trial of cancer drug Envafolimab in India after drug regulator's nod

** Company says clinical trial applications are underway in Russia, Brazil, and Mexico

** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG

** Stock up 27.3% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Shares of Glenmark Pharmaceuticals GLEN.NS up 3.5% to 1985 rupees

** HSBC Global Investment Research retains "buy" rating and PT of 2,380 rupees ($27.20) on GLEN on the back of good visibility on growth drivers

** Easing R&D spend, start of supplies from Monroe plant, U.S. FDA approval for gFlovent, pick-up in the U.S. and India businesses led by new launches are key drivers for GLEN's growth - HSBC

** Stock set to rise most in a session since July 11

** Stock has been above its 100-day, 200-day simple moving avgs since June, indicating bullish sentiment

** Avg rating of nine analysts is "buy" and median PT is 2,380 rupees, ~19% higher than current price - data compiled by LSEG

** YTD, GLEN up ~24%

($1 = 87.5060 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Sept 2 (Reuters) - Glenmark Pharmaceuticals GLEN.NS:

• TO LAUNCH ERIBULIN MESYLATE INJECTION IN USA

• TO BEGIN DISTRIBUTION IN SEPTEMBER 2025

Source text: ID:nBSE5B7S0j

Further company coverage: GLEN.NS

(([email protected];))